Skip to main content

Psoriasis

ALN
In a recent study, researchers investigated whether dose reduction of biologics was noninferior to usual care among patients with well-controlled plaque psoriasis.
The Dermatologist
Results from a small retrospective study suggest adding apremilast to biologic therapy may be a safe and effective option for biologic fatigue among patients with psoriasis.
The Dermatologist
In a recent study that assessed the impact of metabolic conditions on health care costs and treatment outcomes for biologics and apremilast, the researchers found patients with psoriasis and metabolic conditions had higher rates of switching and discontinuation.
The Dermatologist
A recent nationwide population-based cohort study investigated the impact of body weight variability on the risk of developing psoriasis.
The Dermatologist
A phase 3, multicenter, randomized, controlled trial compared the efficacy of guselkumab with secukinumab for achieving PASI 90 after 48 weeks of treatment.
Back to Top